A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: The relevance of the placebo effect and psychological symptoms

Fráguas, Renério; Telles, Renata Martinho da Silva; Alves, Tania C. T. Ferraz; Andrei, Anna Maria; Rays, Jairo; Iosifescu, Dan V.; Wajngarten, Maurı́cio

doi:10.1016/j.cct.2009.01.007

Cited by 45 publications

(59 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 All trials measured depression according to self-report of depressive symptoms, using 1 of several instruments: Beck Depression Inventory I or II, the Center of Epidemiology-Depression, the Geriatric Depression Scale, the Hospital Anxiety and Depression Scale, the Hamilton Rating Scale for Depression, the MontgomeryAsberg Depression Rating Scale, the Multiple Affect Adjective Checklist, the Patient Health Questionnaire, the Profile of Mood States, the Zung Self-Rating Depression Scale, or the Symptom Checklist-Revised. Studies evaluated depression outcomes as depressive symptoms on a continuum, 25,30-45 a dichotomy, [46][47][48] or both. [49][50][51] Effect sizes were estimated for each study if sufficient data were provided.…”

Section: Resultsmentioning

confidence: 99%

“…30,31,46,49 These studies enrolled participants whose left ventricular ejection fractions (LVEFs) were <50%, and who were predominantly male. Inconsistency is demonstrated through differences in direction of effects and significance of differences across studies.…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

“…30,46 Both negative studies reported inadvertently implementing a psychotherapeutic intervention (ie, psychiatric or nursing support) in the control group. This is a plausible explanation for the improvement of depression in those receiving placebo in these 2 studies, and highlights a problem in treating clinical depression in research trials.…”

mentioning

confidence: 99%

“…Among the 4 studies, 1 study received industry funding, 49 1 study did not report funding, 31 and 2 studies reported nonindustry funding. 30,46 The strength of the body of evidence is high that SSRIs are efficacious in the treatment of clinical depression in people with HF. However, the magnitude of effect remains uncertain, and more study is needed among females and those with preserved systolic function.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Effects of interventions on depression in heart failure: A systematic review

et al. 2012

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Effects of interventions on depression in heart failure: A systematic review

et al. 2012

View full text Add to dashboard Cite

“…[97][98][99][100] Use of paroxetine 98 and sertraline 99 reduced depression in 2 of the trials, whereas use of sertraline 97 and citalopram 100 yield no improvement in 2 other trials. The limitation of the 2 studies in which no difference occurred was that the control groups in both studies inadvertently received therapeutic interventions.…”

Section: Effects Of Selective Serotonin Reuptake Inhibitors and Exercisementioning

confidence: 99%

Pathophysiological Relationships Between Heart Failure and Depression and Anxiety

Chapa

Akintade

Son

et al. 2014

Critical Care Nurse

View full text Add to dashboard Cite

H eart failure is an epidemic with national and global implications. Compared with the situation in other cardiac diseases, the incidence and prevalence of heart failure continue to increase despite recent advancements in understanding and treatment. Increased survival after myocardial infarction, aging of the population, and increased incidence of diabetes are contributing factors. This article has been designated for CNE credit. A closed-book, multiple-choice examination follows this article, which tests your knowledge of the following objectives:1. Describe the biopsychosocial holistic model for cardiovascular health 2. Identify 2 neurohormonal pathways and their impact in heart failure 3. Identify nursing implications for heart failure, depression, and anxiety CNE Continuing Nursing EducationCover Depression and anxiety are common comorbid conditions in patients with heart failure. Patients with heart failure and depression have increased mortality. The association of anxiety with increased mortality in patients with heart failure is not established. The purpose of this article is to illustrate the similarities of the underlying pathophysiology of heart failure, depression, and anxiety by using the Biopsychosocial Holistic Model of Cardiovascular Health. Depression and anxiety affect biological processes of cardiovascular function in patients with heart failure by altering neurohormonal function via activation of the hypothalamic-pituitary-adrenal axis, autonomic dysregulation, and activation of cytokine cascades and platelets. Patients with heart failure and depression or anxiety may exhibit a continued cycle of heart failure progression, increased depression, and increased anxiety. Understanding the underlying pathophysiological relationships in patients with heart failure who experience comorbid depression and/or anxiety is critical in order to implement appropriate treatments, educate patients and caregivers, and educate other health professionals. (Critical Care Nurse. 2014;34[2]:14-25)

show abstract

Citalopram versus other anti-depressive agents for depression

Cipriani

Purgato

Furukawa

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second-generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care. Objectives To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression. Search methods We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data. Selection criteria Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants. Data collection and analysis Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side-effects). Main results Thirty-seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non-conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively). Authors’ conclusions Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due ...

show abstract

A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: The relevance of the placebo effect and psychological symptoms

Cited by 45 publications

References 46 publications

Effects of interventions on depression in heart failure: A systematic review

Effects of interventions on depression in heart failure: A systematic review

Pathophysiological Relationships Between Heart Failure and Depression and Anxiety

Citalopram versus other anti-depressive agents for depression

Contact Info

Product

Resources

About